Mark Rus
Directeur Général chez Delix Therapeutics, Inc.
Postes actifs de Mark Rus
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Delix Therapeutics, Inc.
 Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 18/03/2021 | - |
| Directeur Général | 18/03/2021 | - |
Historique de carrière de Mark Rus
Formation de Mark Rus
| London School of Economics & Political Science | Graduate Degree |
| Huron University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Royaume-Uni | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Health Technology |
